The more recent MOUNTAINEER trial [152], a phase II study, compared the combination of tucatinib plus trastuzumab to tucatinib alone in patients with locally advanced or metastatic colorectal cancer (CRC) refractory to chemotherapy and with wild-type KRAS. Here, KRAS is linked to colorectal carcinoma.